Free tool
FAERS Monitor: Naphcon-A
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020226 or its brand name (Naphcon-A, Naphazoline Hydrochloride, Pheniramine Maleate). Reports on generic versions are filed under their own applications.
Reports
295
Serious
28
9% of reports
Hospitalization
5
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective126
- eye irritation55
- eye pain27
- ocular hyperaemia22
- mydriasis20
- vision blurred19
- dry eye12
- headache11
- dizziness10
- eye pruritus10
- fatigue9
- nausea9
- product quality issue9
- expired product administered7
- pain7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 10 |
| 2016 | 31 |
| 2017 | 52 |
| 2018 | 88 |
| 2019 | 9 |
| 2020 | 17 |
| 2021 | 29 |
| 2022 | 12 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 13 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,864 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mydriasisSignal | 20 | 111.3 | 72.9 | 2,075 |
| eye irritationSignal | 55 | 68.2 | 53.7 | 3,581 |
| eye painSignal | 27 | 34.1 | 23.8 | 837 |
| ocular hyperaemiaSignal | 22 | 33.1 | 22.1 | 654 |
| eye pruritusSignal | 10 | 21.2 | 11.5 | 173 |
| dry eyeSignal | 12 | 17.1 | 9.8 | 167 |
| expired product administeredSignal | 7 | 15.0 | 7.2 | 78 |
| vision blurredSignal | 19 | 9.9 | 6.4 | 144 |
| drug ineffectiveSignal | 126 | 6.8 | 6.0 | 661 |
| product quality issueSignal | 9 | 4.7 | 2.5 | 23 |
| dizziness | 10 | 1.4 | 0.8 | 1 |
| headache | 11 | 1.3 | 0.7 | 0 |
| fatigue | 9 | 0.8 | 0.4 | 0 |
| pain | 7 | 0.8 | 0.4 | 0 |
| nausea | 9 | 0.8 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.